system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Aged, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Enzyme-Linked Immunosorbent Assay, Female, Hepatocyte Growth Factor, Humans, Interleukin-6, Lung Neoplasms, Male, Prognosis, Survival Analysis.
user
Are serum hepatocyte growth factor and interleukin-6 effective prognostic markers for non-small cell lung cancer? Context: We surveyed prognostic biomarkers for resectable non-small cell lung cancer (NSCLC). We obtained preoperative serum from 109 patients, and measured the levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), and nicotinamide N-methytransferase (NNMT) in the sera. The median HGF and IL-6 contents were 860 pg/ml and 2.7 pg/ml, respectively. Analysis of survival curves indicated that an HGF or IL-6 level higher than the median was associated with poor overall survival (HGF, p=0.019; IL-6, p=0.002). In addition, we analyzed stage III lung cancer alone. Higher HGF and IL-6 levels were associated with poor overall survival (HGF, p=0.016; IL-6, p=0.013). Disease-free survival was not statistically significantly affected by these cytokine contents. The tumor status (pT factor) and nodal status (pN factor) were not associated with the survival of stage III patients.
assistant
The levels of HGF and IL-6 in serum could be useful prognostic indicators of the survival of patients with stage III NSCLC undergoing surgery and chemotherapy. Final Decision: yes